Lung Cancer Clinical Trial
Official title:
African American Families and Lung Cancer Study
This study will learn more about the beliefs of family members of African American patients
with lung cancer and whether these beliefs are associated with their interest in genetic
testing for disease risk and willingness to participate in genetics research. Lung cancer is
the second most common form of cancer and the leading cause of cancer deaths for men and
women in the United States. Like most cancers, there are racial and ethnic disparities (gaps)
in lung cancer cases and deaths. The age-adjusted rates for blacks and whites (years 2000 to
2003) was 76.9 per 100,000 and 66.0 per 100,000, respectively. Mortality rates were 62.5 per
100,000 for blacks and 55.3 per 100,000 for whites. Cigarette smoking is the most preventable
cause of lung cancer. Findings are that African Americans begin smoking at older ages and
smoke fewer cigarettes per day than Caucasian Americans do. Yet the severity of lung cancer
is greater for African Americans. Behavioral, social, environmental, and genetic factors may
explain the differences.
Participants (subjects) ages 18 to 55 who are family of patients with lung cancer who
self-identify as African Americans may be eligible for this study. Washington, D.C.,
researchers plan to recruit 115 lung cancer patients and 200 family members-100 current
smokers and 100 who never smoked. Lung cancer patients, who must have been born in the United
States, will be recruited from those who are receiving care at the Washington Cancer
Institute at the Washington Hospital Center. They will be asked to list relatives and friends
they consider to be as close as family. Patients will be asked permission for researchers to
contact those people. Family members will receive a letter telling them that unless they
decline to participate, they will be contacted by a telephone interviewer.
The survey will feature questions to evaluate family members' explanations for the causes of
lung cancer, as well as their reactions to possible reasons for the disparity in lung cancer
between African Americans and Caucasian Americans. Subjects will be asked about perceived
personal risk, worry about developing lung cancer, smoking history, motivation to quit
smoking, feelings about the lung cancer patient's diagnosis, racial identify, experience with
racial discrimination, pros and cons of genetic testing, and interest in genetic testing. The
survey will take up to 20 minutes to complete.
This study may or may not have a direct benefit for those who participate. However, lung
cancer patients and their families will be offered a free self-help guide to stop smoking.
They will be referred to local smoking cessation programs. Knowledge gained from the study
may be used to design smoking cessation methods and research studies related to genetics for
minority populations.
The purpose of the African American (AA) Families and Lung Cancer Study is to learn more about (1) the beliefs of family members of AA patients with lung cancer about why AA get lung cancer and (2) whether these beliefs are associated with their interest in genetic testing for lung cancer risk and willingness to participate in clinical genetics research. We plan to recruit 200 AAs (n = 100 current smokers and n = 100 never smokers) who are considered to be as close as family (both biological and non-biological kin) to patients with lung cancer who self-identify as AA (n = 115). Patients will be recruited from Washington Cancer Institute at the Washington Hospital Center in Washington, DC. Family members who self-identify as AA and are between the ages 18 and 55 will be eligible for the study. A Washington Hospital Center recruiter will approach patients and ask their willingness to be contacted for a telephone survey about their general well-being. As part of the survey, patients will be asked to enumerate family and friends who they consider to be as close as family, and asked to specifically focus on those who are current cigarette smokers and those who have never smoked. Patients will be asked to give permission to contact some or all of those enumerated. These family members will be mailed a letter to inform them that unless they call to decline they will be contacted by a telephone interviewer. The survey will include questions to assess family members' explanations for the causes of lung cancer and reactions to possible explanations for disparities in lung cancer between AA and Caucasian Americans (CA), perceived personal risk and worry about developing lung cancer, smoking history, motivation to quit smoking, emotional responses to the patient's diagnosis, racial identity, experience with racial discrimination, pros and cons of genetic testing, and interest in genetic testing (the primary outcome variable). Data analysis using hierarchical linear modeling will assess whether patient characteristics and family members' endorsement of genetics as the cause of lung cancer are associated with their interest in genetic testing and participation in clinical genetics research. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
| Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
| Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
| Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
| Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
| Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
| Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
| Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
| Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|